Bioanalytical method development for momordicinin and its application to long-term pharmacokinetics in diabetic rats

References

• Joseph B, Jini D. Antidiabetic effects of M. omordica charantia (bitter melon) and its medicinal potency. Asian Pac J Trop Dis. 2013;3(2):93–102.
   Google Scholar
• Kumar SR, Ashish J, Satish N. Momordica charantia Linn: a mini review. Int J Biomed Res. 2011;2(11):579–587.
   Google Scholar
• Raman A, Lau C. Anti-diabetic properties and phytochemistry of Momordica charantia L. (Cucurbitaceae). Phytomedicine. 1996;2(4):349–362.
   PubMed Web of Science ®Google Scholar
• Begum S, Ahmed M, Siddiqui BS, et al. Momordica charantia. Phytochemistry. 1997;44(7):1313–1320.
   Web of Science ®Google Scholar
• Prajakta K, Sathiyanarayanan L, Kakasaheb M. Isolation, characterisation and investigation of in vitro antidiabetic and antioxidant activity of phytoconstituents from fruit of Momordica charantia Linn. Nat Prod Res. 2019;35(6):1035–1037.
   PubMed Web of Science ®Google Scholar
• Lin L, Wong H. Predicting oral drug absorption: mini review on physiologically-based pharmacokinetic models. Pharmaceutics. 2017;9(4):41.
   PubMed Web of Science ®Google Scholar
• Wang Y, Avula B, Liu Y, et al. Determination and quantitation of five cucurbitane triterpenoids in Momordica charantia by reversed-phase high-performance liquid chromatography with evaporative light scattering detection. J Chromatogr Sci. 2008;46(2):133–136.
   PubMed Web of Science ®Google Scholar
• Desai S, Tatke P. Charantin: an important lead compound from Momordica charantia for the treatment of diabetes. J Pharmacogn Phytochem. 2015;3(6):163–166.
   Google Scholar
• Tan ES, Abdullah A, Kassim NK. Extraction of steroidal glycoside from small-typed bitter gourd (Momordica charantia L.). J Chem Pharm Res. 2015;7(3):870–878.
   Google Scholar
• Ahamad J, Amin S, Mir SR. Development and validation of HPTLC densitometric method for estimation of charantin in Momordica charantia fruits and herbal formulation. J Pharmacogn Phytochem. 2014;2(5):172–176.
   Google Scholar
• Heise T, Seewaldt-Becker E, Macha S, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15(7):613–621.
   PubMed Web of Science ®Google Scholar
• Pelé-Tounian A, Wang X, Rondu F, et al. Potent antihyperglycaemic property of a new imidazoline derivative S‐22068 (PMS 847) in a rat model of NIDDM. Br J Pharmacol. 1998;124(8):1591–1596.
   PubMed Web of Science ®Google Scholar
• Islam M, Code Q. Streptozotocin is more convenient than Alloxan for the induction of type 2 diabetes. Int J Pharm Res. 2017;7(1):6–11.
   Google Scholar
• Auti P, Gabhe S, Mahadik K. Bioanalytical method development and its application to pharmacokinetics studies on simvastatin in the presence of piperine and two of its synthetic derivatives. Drug Dev Ind Pharm. 2019;45(4):664–668.
   PubMed Web of Science ®Google Scholar
• Yu B, Duan J, Ning H, Huang YL, et al. Pharmacokinetics and metabolism of ulixertinib in rat by liquid chromatography combined with electrospray ionization tandem mass spectrometry. J Sep Sci. 2020;43(7):1275–1283.
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and Research, Food and Drug Administration. Guidance for industry, waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms containing certain active moieties/active ingredients based on a biopharmaceutics classification system; 2018.
   Google Scholar
• Ertan G, Karasulu Y, Güneri T. Degradation and gastrointestinal stability of nitrofurantoin in acidic and alkaline media. Int J Pharm. 1993;96(1–3):243–248.
   Google Scholar
• Stippler E, Kopp S, Dressman JB. Comparison of US Pharmacopeia simulated intestinal fluid TS (without pancreatin) and phosphate standard buffer pH 6.8, TS of the International Pharmacopoeia with respect to their use in in vitro dissolution testing. Dissolution Technol. 2004;11(2):6–11.
   Google Scholar
• Sarkar S, Pranava M, Marita R. Demonstration of the hypoglycemic action of Momordica charantia in a validated animal model of diabetes. Pharmacol Res. 1996;33(1):1–4.
   PubMed Web of Science ®Google Scholar
• Rao PS, Mohan GK. In vitro alpha-amylase inhibition and in vivo antioxidant potential of Momordica dioica seeds in streptozotocin-induced oxidative stress in diabetic rats. Saudi J Biol Sci. 2017;24(6):1262–1267.
   PubMed Web of Science ®Google Scholar
• Liu IM, Hsu FL, Chen CF, et al. Antihyperglycemic action of isoferulic acid in streptozotocin-induced diabetic rats. Br J Pharmacol. 2000;129(4):631–636.
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonisation (ICH). S3B: pharmacokinetics: guidance for repeated dose tissue distribution studies; 1995.
   Google Scholar
• Balap A, Lohidasan S, Sinnathambi A, et al. Herb–drug interaction of Andrographis paniculata (Nees) extract and andrographolide on pharmacokinetic and pharmacodynamic of naproxen in rats. J Ethnopharmacol. 2017;195(4):214–221.
   PubMedGoogle Scholar
• Zhang X, Xia J, Zhang W, et al. Study on pharmacokinetics and tissue distribution of single dose oral tryptanthrin in Kunming mice by validated reversed-phase high-performance liquid chromatography with ultraviolet detection. Integr Med Res. 2017;6(3):269–279.
   PubMed Web of Science ®Google Scholar
• Nikam AR, Sathiyanarayanan L, Mahadik KR. Mapping pharmacokinetic and tissue distribution profile of [6]-shogaol from ginger oleoresin. Int J Pharm Pharm Sci. 2013;5:185–189.
   Google Scholar
• Roffey BW, Atwal AS, Johns T, et al. Water extracts from Momordica charantia increase glucose uptake and adiponectin secretion in 3T3-L1 adipose cells. J Ethnopharmacol. 2007;112(1):77–84.
   PubMed Web of Science ®Google Scholar
• Uebanso T, Arai H, Taketani Y, et al. Extracts of Momordica charantia suppress postprandial hyperglycemia in rats. J Nutr Sci Vitaminol (Tokyo). 2007;53(6):482–488.
   PubMed Web of Science ®Google Scholar